Global Community

Based on current analyst forecasts Terminal PE of 20 as a margin of safety Using my standard discount rate of 15%

Good: Recent sell-off made it reasonably priced Has decent returns (24% ROE, 11% ROIC) Good and stable shareholder yield (dividend 2.1% yield with 10+% growth + buybacks) Very stable and decent past growth both top and bottom line Has a wide moat STR BUY forecast Bad: Really really bad PR Threat of high fines Low margins - highly affected by med costs raising Current/Quick ratios below 1 (around 0.85)

Miss Expectation Revenue: US$6.22b (down 9.7% from FY 2023). Net loss: US$1.34b (loss widened by US$1.32b from FY 2023).

Risks -27% stock price drop over past year – industry-wide pressure Cyclicality – tied to industrial demand cycles Moderate growth – not a high-growth tech stock Assumptions Revenue by 2029: Estimate: ~SEK 26–28 billion Current Revenue: SEK 20.44 billion Expected Growth: ~4.3–7.2% annually Growth Drivers: Strong demand for polymer solutions in automotive, construction, and energy Growth in engineered products and thermoplastic elastomers Sustainability and recycling focus aligned with EU regulations (ESG boost) Earnings by 2029: Estimate: ~SEK 3–3.5 billion Current Earnings: SEK 2.22 billion Expected Growth: ~7.2% annually Key Factors: Stable gross margins (21–23%) Facility consolidation and improved operational efficiency Acquisitions (M&A) and shift toward high-margin products Catalysts Reliable dividend yield – 4.3% Low debt (Debt/Equity = 18.7%) Consistent growth through green innovation and acquisitions

Assumptions: Continued growth of 15% Profit Margin of 15% by 2030 Terminal PE of 20 Discount rate: 15%

Gewinnwarnung 2024: Gestiegende Transportkosten Preissensititivät d. Kunden Geringes Wirtschaftswachstum 2-4 % CAGR "Low End of Guidance hard to achive" Gewinnwarnungen auch von Produzenten BASF, Lanxess, Evonik Umsatzwachstum "nur" 5,1 % (< erwartete 9...10%) stagnierender Marktausblick Chemieindustrie (gestiegende Energiekosten), ggf.

Yes

In 5 years, the company should significantly expand its portfolio of stores in countries other than Poland, open up to new markets, and introduce e-commerce and applications of its brands to new countries. Due to the fact that it has five brands, each targeting a different audience, the company has a wide scope for action and further development, as the brands it has are not in competition with each other, but complement each other perfectly.

I think that Pfizer has a strong pipeline. The aquisition of seagen added many new oncology products that will continue to grow by 14% partially offseting the decline on sales of the covid-19 vaccines.